Sanofi, Transgene to Build Joint Lab to Develop Anti Cancer Drugs
January 29 2014 - 2:29AM
Dow Jones News
By Inti Landauro
PARIS--French pharmaceutical giant Sanofi SA (SAN.FR) said
Wednesday that it will build a joint lab with partner Transgene SA
(TNG.FR) to manufacture viral vectors such as MUC1, a drug
developed by Transgene that targets cancer immunotherapy.
The lab will be located in Lyon and will cost EUR10 million over
two years, with each company financing half the cost, Sanofi and
Transgene said in a joint statement.
The two companies had announced a partnership in March last
year.
Write to Inti Landauro at inti.landauro@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024